Dr. Schuster shares results from the global JULIET trial of the CAR T-cell therapy tisagenlecleucel in patients with relapsed/refractory diffuse large B-cell lymphoma – a patient population with the “greatest unmet need.”
Recent Articles
Early Results Show Moderna’s COVID-19 Vaccine is 95% Effective
Moderna shared early findings that show its experimental coronavirus vaccine was 94.5% effective at preventing COVID-19.
In a study of 30,000 people, 95 developed symptomatic...
FDA Grants Emergency Use Authorization to Bamlanivimab for COVID-19
The FDA has granted emergency use authorization to bamlanivimab, an antibody treatment for COVID-19.
“It’s a great day for science and medicine,” said Daniel Skovronsky,...
U.S. States, Hospitals Rush to Buy Vaccine Freezers
Following news of initial results showing that the vaccine developed by Pfizer and German partner BioNTech 22UAy.F was more than 90% effective, U.S. states,...
What Do COVID-19 Infections in Animals Mean for Humans?
Scientists and animal conservationists are investigating the vulnerability of animals to the coronavirus and the implications of infected animals passing the virus to humans.
After...
CSL889 Receives Orphan Drug Designation for Sickle Cell Disease
The FDA and the European Commission have granted orphan drug designation to CSL889, a plasma-derived hemopexin therapy, for the treatment of sickle cell disease...
Current Issue
November 2020 Bonus ASH Annual Meeting Preview Edition (Volume 6, Issue...
View issue flipbook
November 2020 Bonus ASH Annual Meeting Preview Edition
Volume 6, Issue 14This issue offers a behind-the-scenes look at this year's virtual annual meeting,...